**Table S1.** Characteristics of included sarcomas.

|  |  |  |  |
| --- | --- | --- | --- |
| **Standardised diagnosis** | **Local Sarcoma at Diagnosis** | **Metastatic Sarcoma at Diagnosis**N=69 | **All Patients**N=358 |
| No further metastatic diseaseN=213 | Furthermetastatic diseaseN=76 |
| Sarcoma NOS | 69 (32.4%) | 32 (42.1%) | 26 (37.7%) | 127 (35.5%) |
| Leiomyosarcoma | 42 (19.7%) | 10 (13.2%) | 16 (23.2%) | 68 (19.0%) |
| Angiosarcoma | 12 (5.6%) | 5 (6.6%) | 9 (13.0%) | 26 (7.3%) |
| Uterine leiomyosarcoma | 8 (3.8%) | 10 (13.2%) | 7 (10.1%) | 25 (7.0%) |
| Myxofibrosarcoma | 19 (8.9%) | 3 (3.9%) | 0 (0.0%) | 22 (6.1%) |
| Endometrial stromal sarcoma  | 14 (6.6%) | 1 (1.3%) | 2 (2.9%) | 17 (4.7%) |
| Synovial sarcoma | 10 (4.7%) | 5 (6.6%) | 0 (0.0%) | 15 (4.2%) |
| Malignant peripheral nerve sheath tumour | 11 (5.2%) | 0 (0.0%) | 0 (0.0%) | 11 (3.1%) |
| Solitary malignant fibrous tumour | 6 (2.8%) | 2 (2.6%) | 1 (1.4%) | 9 (2.5%) |
| Low grade fibromyxoid sarcoma | 6 (2.8%) | 0 (0.0%) | 0 (0.0%) | 6 (1.7%) |
| Epithelioid sarcoma | 4 (1.9%) | 0 (0.0%) | 1 (1.4%) | 5 (1.4%) |
| Fusiform cell sarcoma | 2 (0.9%) | 2 (2.6%) | 1 (1.4%) | 5 (1.4%) |
| Others | 10 (4.7%) | 6 (7.9%) | 6 (8.7%) | 22 (6.1%) |